Market Closed - Xetra 11:35:07 2024-07-12 am EDT 5-day change 1st Jan Change
8.955 EUR -4.02% Intraday chart for Evotec SE -7.87% -57.92%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Deutsche Bank downgrades Evotec to 'Hold' - annual targets at risk DP
EVOTEC : Deutsche Bank is less optimistic ZD
Pfizer: collaboration agreement with Evotec in France CF
Sector Update: Health Care Stocks Steady Premarket Wednesday MT
Evotec, Pfizer Enter Research Collaboration on Metabolic, Infectious Diseases MT
Evotec, Pfizer Team Up for Early Drug Discovery for Metabolic, infectious Diseases MT
Evotec with new recovery attempt - cooperation with Pfizer DP
Evotec and Pfizer Collaborate to Advance Drug Discovery in France CI
EVOTEC : Deutsche Bank reiterates its Buy rating ZD
EVOTEC : Buy rating from RBC ZD
Sandoz collaboration extension helps Evotec back to May high DP
Evotec's Biologics Segment Expands Sandoz Partnership MT
EVOTEC : RBC reiterates its Buy rating ZD
Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board CI
German Stocks Rise for Second Session DJ
German Stocks Reverse Two-Session Losing Streak DJ
Sector Update: Health Care Stocks Advance Pre-Bell Tuesday MT
Evotec Gets $39 Million Contract With U.S. Defense Department DJ
Evotec Unit Bags Contract to Develop Accelerated Antibody Manufacturing Platform for US Government MT
Evotec Subsidiary Gets Multi-Year US Defense Department Contract for Up to $39 Million MT
Evotec receives additional contract from US Department of Defense DP
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15 DP
Evotec In Talks With Advisers Amid Takeover Worries MT
European shares advance on tech, real estate boost; Swiss stocks shine RE
Takeover fantasy drives Evotec recovery DP
Chart Evotec SE
More charts
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
8.955 EUR
Average target price
20.72 EUR
Spread / Average Target
  1. Stock Market
  2. Equities
  3. EVT Stock
  4. News Evotec SE
  5. Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb